CollPlant Biotechnologies Ltd.

CLGN

IL0004960188

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 11:11:26 2024-04-25 am EDT			5-day change	1st Jan Change
5.36 ^USD	-0.92%		+2.68%	-16.12%

Apr. 04	CollPlant Biotechnologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 02	CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants	CI

CollPlant Biotechnologies Ltd.(NasdaqGM:CLGN) added to S&P Global BMI Index

September 20, 2021 at 12:00 am EDT

Latest news about CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 04	CI
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants	Jan. 02	CI
Earnings Flash (CLGN) COLLPLANT Posts Q3 Revenue $43,000	Nov. 29	MT
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
CollPlant Biotechnologies Issued US Patent for Photocurable Dermal Filler	Nov. 01	MT
Wall Street Set to Open Slightly Higher; Weekly Jobless Claims Fall to Near Historic Lows	23-10-19	MT
Top Premarket Decliners	23-10-19	MT
Earnings Flash (CLGN) COLLPLANT Reports Q2 Revenue $10.2M	23-08-24	MT
Earnings Flash (CLGN) COLLPLANT Posts Q2 EPS $0.52	23-08-24	MT
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
CollPlant to Receive $10 Million Milestone Payment From AbbVie Under Dermal Filler Product Deal; Shares Rise	23-06-26	MT
CollPlant Biotechnologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-24	CI
Stratasys, CollPlant Biotechnologies to Bio-Fabricate Human Tissues, Organs	23-04-04	MT
Stratasys Ltd. and Collplant Biotechnologies Ltd. to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs	23-04-04	CI
HC Wainwright Adjusts Price Target on CollPlant Holdings to $11 From $26, Maintains Buy Rating	23-03-30	MT
CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives	23-01-04	CI
Collplant Enriches Portfolio of Rhcollagen-Based Bioinks with Launch of Collink.3Dtm 50L in Powder Form	23-01-03	CI
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-12-01	CI
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-12-01	CI
Earnings Flash (CLGN) COLLPLANT Posts Q3 Revenue $109,000	22-12-01	MT
Earnings Flash (CLGN) COLLPLANT Posts Q3 Loss $-0.34	22-12-01	MT
CollPlant, Tel Aviv University, Sheba Medical Center to Co-Develop Tissue Model for Drug Discovery to Treat Ulcerative Colitis	22-11-15	MT
Collplant Enters into A License and Research Agreement to Co-Develop A “Gut-On-A-Chip” Tissue Model for Drug Discovery and High Throughput Screening of Drugs	22-11-15	CI
CollPlant Biotechnologies Ltd., Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis	22-11-15	CI
Collplant Expands Rhcollagen-Based Bioink Platform with Launch of Collink.3D 90	22-11-07	CI

Chart CollPlant Biotechnologies Ltd.

Duration

Period

More charts

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).

Sector

Biotechnology & Medical Research

Calendar

2024-05-22 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for CollPlant Biotechnologies Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.41 USD

Average target price

11 USD

Spread / Average Target

+103.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Medical Devices

	1st Jan change	Capi.
COLLPLANT BIOTECHNOLOGIES LTD.	-16.12%	61.96M
MIMEDX GROUP, INC.	-30.05%	949M
NIBEC CO., LTD.	-20.09%	131M
KIM FOREST ENTERPRISE CO., LTD.	+7.05%	60.9M
BONUS BIOGROUP LTD.	+0.60%	52.2M

Bio Medical Devices